China Top Pharmaceutical Companies Insight


Kuick Research Recent Publication Highlights Top 330 Domestic Pharmaceutical Companies In China

Delhi, Sept. 04, 2023 (GLOBE NEWSWIRE) — China Pharmaceutical Companies Database & Drugs Pipeline Insight 2023 Highlights:

  • All Companies Are Domestic Chinese Companies
  • Chinese Pharmaceuticals Companies Business Overview Insight: 330 Companies
  • Comprehensive Insight On Drugs In Clinical Trials By Companies: > 1500 Drugs
  • Clinical Trials Insight By Companies, Indication, Formulation & Phase
  • Comprehensive Insight On Drugs Commercially Approved In Market: > 200 Drugs
  • Biosimilar, Branded & Generics Drugs Classification


Download Sample:

China is home to some of the largest pharmaceutical companies in the world like BeiGene, Akeso, Hengrui Medicine and Hansoh Pharmaceutical. These companies have left a mark on the global pharmaceutical industry in different aspects, which has allowed them, and China, to be viewed as credible players in the global pharmaceutical industry. Akeso developed and received regulatory approval for the world’s first dual checkpoint inhibitor – Cadonilimab – highlighting the various developments and enhancements in China’s pharmaceutical market. In fact, China was also the first country to approve the commercialization of gene therapies, years before the US FDA.

The government of China has also aided in expanding the pharmaceutical market of the region by formulating policies to encourage more domestic as well as international pharmaceutical companies to view China as a dependable market for drug development. Healthy China 2030 is one such example of the government’s agendas to help expand the regional pharmaceutical industry and have substantial impacts on health of its citizens. Therefore, the Chinese pharmaceutical market is poised to grow at unprecedented rates as investments and companies pour into the regional market.

CONTACT: Neeraj Chawla Kuick research Research Head [email protected]

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.